Phase 2 randomised trial, repurposing Danazol and VBaP in low-risk myelodysplastic syndrome: REPAIR MDS

被引：0
|
作者：
Raghavan, Manoj [3 ]
Jenkins, Stephen [1 ,2 ]
Wintrich, Sophie [4 ]
Drayson, Mark [3 ]
Bunce, Chris [3 ]
Culligan, Dominic [5 ]
Kulasekararaj, Austin [6 ,7 ]
Wiseman, Dan [8 ,9 ]
Foster, Bethany [1 ]
Dunn, Janet [1 ]
机构：
[1] Univ Warwick, Coventry, W Midlands, England
[2] Dudley Grp NHS Fdn Trust, Dudley, England
[3] Univ Birmingham, Birmingham, W Midlands, England
[4] MDS UK Support Grp, London, England
[5] Aberdeen Royal Infirm, Aberdeen, Scotland
[6] Kings Coll Hosp London, London, England
[7] Kings Coll London, London, England
[8] CRCUK Manchester, Machester, England
[9] Christie NHS Fdn Trust, Machester, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH23-EP17
引用
收藏
页码：153 / 153
页数：1
相关论文
共 50 条
  • [21] Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome
    Ramon Gonzalez-Porras, Jose
    Cordoba, Iris
    Such, Esperanza
    Nomdedeu, Benet
    Vallespi, Teresa
    Carbonell, Felix
    Luno, Elisa
    Ardanaz, Maite
    Ramos, Fernando
    Pedro, Carme
    Gomez, Valle
    de Paz, Raquel
    Sanchez-Barba, Mercedes
    Sanz, Guillermo F.
    del Canizo, Consuelo
    CANCER, 2011, 117 (24) : 5529 - 5537
  • [22] Amifostine plus erythropoietin in a patient with low-risk myelodysplastic syndrome
    Musch, E
    Malek, M
    Chrissafidou, A
    ANNALS OF HEMATOLOGY, 2003, 82 (04) : 244 - 246
  • [23] Pathogenesis of iron overload in myelodysplastic syndromes and the debate on iron chelation in low-risk MDS
    Shenoy, Niraj
    Verma, Amit
    Ginzburg, Yelena
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S85 - S85
  • [24] Incidence of Autoimmunity in Patients (pts) with Low-Risk (LR) Myelodysplastic Syndrome (MDS): 10 Years Follow-up
    Elkhanany, Ahmed
    Hanson, Curtis A.
    Patnaik, Mrinal
    Elliott, Michelle
    Litzow, Mark
    Al-Kali, Aref
    BLOOD, 2012, 120 (21)
  • [25] Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
    Oliva, Esther Natalie
    Riva, Marta
    Niscola, Pasquale
    Santini, Valeria
    Breccia, Massimo
    Giai, Valentina
    Poloni, Antonella
    Patriarca, Andrea
    Crisa, Elena
    Capodanno, Isabella
    Salutari, Prassede
    Reda, Gianluigi
    Cascavilla, Nicola
    Ferrero, Dario
    Guarini, Attilio
    Tripepi, Giovanni
    Ianni, Giuseppe
    Russo, Emilio
    Castelli, Andrea
    Fattizzo, Bruno
    Beltrami, Germana
    Bocchia, Monica
    Molteni, Alfredo
    Fenaux, Pierre
    Germing, Ulrich
    Ricco, Alessandra
    Palumbo, Giuseppe A.
    Impera, Stefana
    Di Renzo, Nicola
    Rivellini, Flavia
    Buccisano, Francesco
    Stamatoullas-Bastard, Aspasia
    Liberati, Anna Marina
    Candoni, Anna
    Delfino, Ilaria Maria
    Arcadi, Maria Teresa
    Cufari, Patrizia
    Rizzo, Lorenzo
    Bova, Irene
    D'Errigo, Maria Grazia
    Zini, Gina
    Latagliata, Roberto
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (28) : 4486 - +
  • [26] Baseline predictors of response to treatment with darbepoetin-alpha (DA) in anemic patients with low-risk myelodysplastic syndrome (MDS)
    Gabrilove, J.
    Paquette, R.
    Lyons, R.
    Mushtaq, C.
    Sekeres, M.
    Tomita, D.
    Lillie, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] IS IT POSSIBLE TO DIAGNOSE LOW RISK MYELODYSPLASTIC SYNDROME (MDS) BY FLOW CYTOMETRY?
    Atilla, E.
    Atilla, P. Ataca
    Turedi, O.
    Bozdag, S. Civriz
    Toprak, S. Kocak
    Akan, H.
    Beksac, M.
    Arslan, O.
    Topcuoglu, P.
    Ozcan, M.
    Ilhan, O.
    Ruhi, H. I.
    Gurman, G.
    Dalva, K.
    HAEMATOLOGICA, 2016, 101 : 506 - 506
  • [28] Antithymocyte globulin (ATG) has limited efficacy in anemic patients with low-risk myelodysplastic syndrome (MDS): Results of a prematurely terminated phase IItrial.
    Steensma, DP
    Dispenzieri, A
    Schroeder, G
    Tefferi, A
    BLOOD, 2002, 100 (11) : 338B - 338B
  • [29] Eltrombopag Improves Hematopoiesis in Patients with Low to Intermediate-2 Risk Myelodysplastic Syndrome (MDS)
    Vicente, Alana
    Gutierrez-Rodrigues, Fernanda
    Giudice, Valentina
    Wu, Zhijie
    Kajigaya, Sachiko
    Ibanez, Maria del Pilar Fernandez
    Albitar, Maher
    Weinstein, Barbara
    Calvo, Katherine R.
    Townsley, Danielle M.
    Scheinberg, Phillip
    Dunbar, Cynthia E.
    Young, Neal S.
    Winkler, Thomas
    BLOOD, 2018, 132
  • [30] Phase 1b Trial of Irak 1/4 Inhibition for Low-Risk Myelodysplastic Syndrome Refractory/Resistant to Prior Therapies: A Trial in Progress
    Garcia-Manero, Guillermo
    Silverman, Lewis R.
    Yan, Lucy
    BLOOD, 2023, 142
12345